Affymetrix AFFX

  1. All
  2. Commentary
  3. Headlines
    1. Biophotonics Market to Grow at 11.3% CAGR from 2014 to 2020


      Tue, 26 May 2015

      Global Biophotonics Market – Competition Landscape 8.1. Company Profiles 8.1.1. Becton, Dickinson & Co. 8.1.2. Affymetrix Inc. 8.1.3. Carl Zeiss 8.1.4. Olympus America 8.1.5. Andor Technology 8.1.6. Hamamatsu Photonics 9

    2. Affymetrix estimates revenue below Street expectations, shares fall


      Mon, 8 Oct 2012

      (Reuters) - Affymetrix Inc estimated third-quarter revenue that was below Wall Street expectations, as tightening academic funding worldwide reduced sales at its gene expression and eBioscience...

    3. Dropping Coverage of Affymetrix


      Mon, 29 Aug 2011

      We are no longer providing equity research on Affymetrix AFFX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    4. Affymetrix shares fall on weak Q2 revenue view


      Thu, 7 Jul 2011

      (Reuters) - Shares of Affymetrix Inc fell about 20 percent on Thursday, a day after the genetic analysis products maker reported preliminary second-quarter revenue below market expectations.

    5. Affymetrix Turns Profit in 3Q


      Fri, 12 Nov 2010

      Affymetrix AFFX swung to profitability in the third ..... needle on our fair value estimate. Affymetrix reported $74 million in sales, 5 ..... cancer research. On the capital front, Affymetrix has continued to repurchase its convertible

    6. Revenue Drops in Affymetrix's 2Q


      Fri, 23 Jul 2010

      Affymetrix AFFX reported second-quarter results with revenue that came within its ..... Diagnostics to launch a colorectal cancer test. These efforts underpin Affymetrix 's efforts to focus investments on validation and diagnostic testing

    7. Affymetrix Lowers Revenue Outlook


      Wed, 7 Jul 2010

      Affymetrix AFFX today lowered its second-quarter revenue outlook to a range of $71 ..... decline. Lower second-quarter revenue will make it difficult for Affymetrix to achieve our full-year sales projections, and we are considering

    8. New Credit Rating: Illumina


      Wed, 23 Jun 2010

      ensure its dominance beyond the current technology cycle. For example, the recent downfall of former niche leader Affymetrix AFFX (rating: BB-) reads like a cautionary tale for Illumina creditors. Beyond those high business risks, we think

    9. New Credit Rating: Affymetrix


      Fri, 23 Apr 2010

      our issuer credit rating for Affymetrix AFFX at BB - , firmly in junk territory ..... genetic analysis niche , and Affymetrix has become a laggard , falling ..... before . While we still think Affymetrix will be able to sell its diagnostic

    10. In-Line 1Q for Affymetrix


      Thu, 22 Apr 2010

      Affymetrix AFFX reported first - quarter results in line with our expectations . We will maintain our fair value estimate as we still have worries

    « Prev1234Next »
    Content Partners